Quality of Life of Schizophrenic Patients on Medications and Implications for New Drug Trials
Abstract
The quality of life of schizophrenic patients participating in clinical trials of new neuroleptics is rarely systematically assessed. Factors that may have contributed to the neglect of such assessments include the difficulty of measuring changes affecting quality of life during short-term trials and the continued belief that schizophrenic patients' self-reports about inner states are unreliable. A model of determinants specifically related to the quality of life of schizopbrenic patients in such trials would include symptoms, side effects of neuroleptics, and psychosocial performance. In view of the importance of assessing the quality of life of patients on medications, the author recommends that regulatory agencies require such assessments in clinical trials of new neurokptics.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
